Colleen Niswender Archives
Aug. 24, 2017—Vanderbilt University research-ers have relieved symptoms of Rett syndrome in a mouse model with a small molecule that works like the dimmer switch in an electrical circuit.
Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.
Nov. 17, 2016—Vanderbilt’s Rett Syndrome Clinic has been named a Rett Syndrome Clinical Research Center of Excellence by Rettsyndrome.org.
Mar. 3, 2016—Researchers at Vanderbilt University Medical Center have relieved symptoms in a mouse model of Rett syndrome with a drug-like compound that works like the dimmer switch in an electrical circuit.
Jan. 23, 2014—Colleen Niswender, Ph.D., research associate professor of Pharmacology, has received a three-year, $450,000 grant from the autism science and advocacy organization Autism Speaks to support studies investigating a possible new treatment for Rett syndrome.
Sep. 30, 2011—Drug-like molecules described by Vanderbilt researchers could lead to Parkinson's treatments with fewer side effects.
Mar. 11, 2011—Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain.